Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Sjælland Forside
Hjælp og OSS
Link åbnes på en ny fane
Dansk
English
Søg efter indhold i Region Sjælland
Forside
Profiler
Forskningsenheder
Projekter
Publikationer
Priser
Aktiviteter
Undervisning og vejledning
Presse/medier
Impacts
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
M. R. Mirza
*
, B. J. Monk
,
J. Herrstedt
, A. M. Oza
, S. Mahner
, A. Redondo
, M. Fabbro
, J. A. Ledermann
, D. Lorusso
, I. Vergote
, N. E. Ben-Baruch
, C. Marth
, R. Madry
, R. D. Christensen
, J. S. Berek
, A. Dørum
, A. V. Tinker
, A. Du Bois
, A. González-Martín
, P. Follana
B. Benigno, P. Rosenberg, L. Gilbert, B. J. Rimel, J. Buscema, J. P. Balser, S. Agarwal, U. A. Matulonis
Vis 8 andre
Vis mindre
*
Corresponding author af dette arbejde
Publikation
:
Bidrag til tidsskrift
›
Artikel
›
Forskning
›
peer review
Oversigt
Fingeraftryk
Fingeraftryk
Udforsk hvilke forskningsemner 'Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer' indeholder.
Sorter
Vægt
Alfabetisk
Medicine and Dentistry
Maintenance Therapy
100%
Niraparib
100%
Recurrent Ovarian Cancer
100%
Platinum
100%
Placebo
66%
Hazard Ratio
33%
Progression Free Survival
33%
Homologous Recombination
22%
Anemia
11%
Ovarian Cancer
11%
BRCA Mutation
11%
Neutropenia
11%
Thrombocytopenia
11%
Poly ADP Ribose Polymerase
11%
Bone Marrow Toxicity
11%
Germ Cell
11%
Oral
11%
Tumor
11%
Adverse Event
11%
Keyphrases
Maintenance Therapy
100%
Niraparib
100%
Placebo
55%
Hazard Ratio
33%
Progression-free Survival
33%
95% Confidence Interval
33%
Homologous Recombination Deficiency
22%
Once-daily
11%
Randomized Double-blind
11%
Tumor
11%
Adverse Events
11%
Anemia
11%
Germline BRCA mutation
11%
Ovarian Cancer
11%
Clinical Activity
11%
Neutropenia
11%
Thrombocytopenia
11%
Dose Adjustment
11%
Maintenance Treatment
11%
Placebo Groups
11%
Phase 3 Trial
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Niraparib
100%
Platinum
100%
Placebo
66%
Progression Free Survival
33%
Adverse Event
11%
Thrombocytopenia
11%
Anemia
11%
Neutropenia
11%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
11%
Bone Marrow Toxicity
11%